Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord mesenchymal stem cell (UC-MSC) secretome is a cell-free therapeutic agent developed by PT. Prodia Stem Cell Indonesia for the treatment of androgenetic alopecia. It consists of a complex mixture of bioactive molecules, including growth factors, cytokines, and extracellular vesicles (exosomes), secreted by UC-MSCs during culture. These components are thought to stimulate hair follicle regeneration by promoting the proliferation of dermal papilla cells, inducing the anagen phase of the hair cycle, and reducing inflammation. In clinical studies, it is administered via intradermal injection into the scalp to improve hair density and the terminal-to-vellus hair ratio.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord mesenchymal stem cell secretome.